{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:46:26Z","timestamp":1792813586352,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Stereotactic body radiation therapy (SBRT) is an important modality in treatment of tumors. We hypothesized that SBRT can achieve excellent local control with limited toxicity in patients with thymic tumors. A single-institution prospective study was performed with 32 patients who underwent SBRT of thymoma and thymic carcinoma between 2005 and 2014. Thirty-two patients including 39 target lesions were analyses in this study. Almost half of the patients (46.9%) were type C by histopathology and more than half (56.3%) were classified into stage IVA or IVB. The median dose of SBRT for gross tumor volume (GTV) was 56\u2009Gy (range 49\u201370\u2009Gy). Results showed that the response rate was 96.9% after SBRT and the median tumor shrinkage rate was 62.2% (range 3.8\u2013100%). For the patients with both stage II\u2013III and type A-B (n\u2009=\u20096), the median PFS was 28 months. In-field failure was only observed in 4 patients, and outside-field failure was seen in 2 patients. The local control rate was 81.25%. Patients treated with SBRT had an excellent local control with mild toxicities, which suggests that SBRT is feasible for the patients with thymic tumors who are unable to undergo either surgery or conventionally fractionated radiation therapy.<\/jats:p>","DOI":"10.1038\/s41598-017-12909-z","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T10:12:02Z","timestamp":1507889522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prospective Study of Stereotactic Body Radiation Therapy for Thymoma and Thymic Carcinoma: Therapeutic Effect and Toxicity Assessment"],"prefix":"10.1038","volume":"7","author":[{"given":"Xue-jun","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zejun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9018-7053","authenticated-orcid":false,"given":"Xue-qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"key":"12909_CR1","unstructured":"Travis, W. et al. Pathology and genetics of tumorsof the lung, pleura, thymus and heart. WHO Classification ofTumors. Lyon: IARC Press. 145\u2013197 (2004)."},{"key":"12909_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.athoracsur.2009.08.074","volume":"89","author":"S Margaritora","year":"2010","unstructured":"Margaritora, S., Cesario, A. & Cusumano, G. et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. A. Thorac Surg. \n                           89, 245\u201352 (2010).","journal-title":"A. Thorac Surg."},{"key":"12909_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/1759-7714.12320","volume":"7","author":"JP Xu","year":"2016","unstructured":"Xu, J. P. et al. Efficacy and safety of the combination of paclitaxel and platinum in advanced thymic carcinoma. Thorac Cancer. \n                           7, 222\u2013225 (2016).","journal-title":"Thorac Cancer."},{"key":"12909_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00066-014-0740-z","volume":"191","author":"MMF H\u00e4fner","year":"2015","unstructured":"H\u00e4fner, M. M. F. et al. Postoperative radiotherapy of patients with thymic epithelial tumors. J. S U Onkol. \n                           191, 133\u201340 (2015).","journal-title":"J. S U Onkol."},{"key":"12909_CR5","first-page":"49","volume":"6","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y. et al. Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer. T. Cancer. \n                           6, 49\u201357 (2015).","journal-title":"Cancer."},{"key":"12909_CR6","doi-asserted-by":"crossref","unstructured":"Preston, D. L. et al. Studies of mortality ofatomic bomb survivors. Report 13: solid cancer and noncancer diseasemortality: 1950\u20131997. 2003. Radio Res. 178, AV146\u201372 (2012).","DOI":"10.1667\/RRAV12.1"},{"key":"12909_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/COC.0b013e318042d566","volume":"30","author":"Y Kundel","year":"2007","unstructured":"Kundel, Y. et al. Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors. A J of Clin Oncol. \n                           30, 389\u201394 (2007).","journal-title":"A J of Clin Oncol."},{"key":"12909_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/0360-3016(95)00079-E","volume":"32","author":"F Mornex","year":"1995","unstructured":"Mornex, F. et al. Radiotherapy and chemotherapy for invasive thymomas: A multicentric retrospective review of 90 cases. Inter J of Radio Oncol*Bio*Phy. \n                           32, 651\u2013659 (1995).","journal-title":"Inter J of Radio Oncol*Bio*Phy."},{"key":"12909_CR9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/jrr\/rrw028","volume":"57","author":"Y Matsuo","year":"2016","unstructured":"Matsuo, Y., Yoshida, K. & Nishimura, H. et al. Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis\/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy. J of Radi Res \n                           57, 512\u2013523 (2016).","journal-title":"J of Radi Res"},{"key":"12909_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.08.033","volume":"96","author":"JM Stahl","year":"2016","unstructured":"Stahl, J. M. & Ross, R. et al. The effect of biologically effective dose and radiation treatment schedule on overall survival in stage i non-small cell lung cancer patients treated with stereotactic body radiation therapy. Inter J of Radi Oncol Bio Phy \n                           96, 1011 (2016).","journal-title":"Inter J of Radi Oncol Bio Phy"},{"key":"12909_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.radonc.2012.06.007","volume":"104","author":"I Fotina","year":"2012","unstructured":"Fotina, I. et al. Feasibility of CBCT-based dose calculation: Comparative analysis of HU adjustment techniques - Radiotherapy and Oncology. Radio & Oncol J of the Europ Society for T Radio &Oncol. \n                           104, 249\u201356 (2012).","journal-title":"Radio & Oncol J of the Europ Society for T Radio &Oncol."},{"key":"12909_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0167-8140(03)00003-3","volume":"67","author":"V Moiseenko","year":"2003","unstructured":"Moiseenko, V., Craig, T., Bezjak, A., Van & Dyk, J. Dose\u2013volume analysis of lung complications in the radiation treatment of malignant thymoma: a retrospective review. Radio Oncol. \n                           67, 265\u201374 (2003).","journal-title":"Radio Oncol."},{"key":"12909_CR13","first-page":"300","volume":"165","author":"CM Lee","year":"2016","unstructured":"Lee, C. M. et al. Treatment of Thymoma-Associated Myasthenia Gravis With Stereotactic Body Radiotherapy: A Case Report. Ann of Inter. Medicine, Aug 16 \n                           165, 300\u20131 (2016).","journal-title":"Medicine, Aug 16"},{"key":"12909_CR14","first-page":"129","volume":"6","author":"R Fan","year":"2009","unstructured":"Fan, R. et al. Clinical analysis of 45 patients with thymic carcinoma. Cancer Bio and Medic. \n                           6, 129\u2013132 (2009).","journal-title":"Cancer Bio and Medic."},{"key":"12909_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clon.2012.12.005","volume":"25","author":"AM Baschnagel","year":"2013","unstructured":"Baschnagel, A. M. et al. Lung metastases treated with image-guided stereotactic body radiation therapy. Clin Oncol \n                           25, 236\u201341 (2013).","journal-title":"Clin Oncol"},{"key":"12909_CR16","doi-asserted-by":"publisher","DOI":"10.3747\/co.22.2693","volume":"22","author":"CY Y. Fan","year":"2015","unstructured":"Y. Fan, C. Y. et al. Stereotactic ablative radiotherapy with CyberKnife for advanced thymic carcinoma: a case report. Curr Oncol. \n                           22, e391 (2015).","journal-title":"Curr Oncol."},{"key":"12909_CR17","volume":"9","author":"Y Harada","year":"2017","unstructured":"Harada, Y. et al. Thymic carcinoma treated by cyberknife stereotactic body radiotherapy. Cureus \n                           9, e1056 (2017).","journal-title":"Cureus"},{"key":"12909_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF02743578","volume":"175","author":"R Mayer","year":"1999","unstructured":"Mayer, R. et al. Radiotherapy for invasive thymoma and thymic carcinoma. Clinicopathological review. Strahlenther Onkol. \n                           175, 271\u20138 (1999).","journal-title":"Strahlenther Onkol."},{"key":"12909_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/cncr.29166","volume":"121","author":"M Omasa","year":"2015","unstructured":"Omasa, M. et al. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database Study. Cancer. \n                           121, 1008\u201316 (2015).","journal-title":"Cancer."},{"key":"12909_CR20","first-page":"S327","volume":"5","author":"CD Fuller","year":"2010","unstructured":"Fuller, C. D. et al. Radiotherapy for thymic neoplasms. J of T Oncol Official Pub of the Inter A for the Study of Lung Cancer \n                           5, S327\u201335 (2010).","journal-title":"J of T Oncol Official Pub of the Inter A for the Study of Lung Cancer"},{"key":"12909_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fonc.2013.00330","volume":"3","author":"R Komaki","year":"2014","unstructured":"Komaki, R. & Gomez, D. R. Radiotherapy for Thymic Carcinoma: Adjuvant, Inductive, and Definitive. Frontiers in Oncol. \n                           3, 330\u2013330 (2014).","journal-title":"Frontiers in Oncol."},{"key":"12909_CR22","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","volume":"15","author":"PJ Loehrer Sr.","year":"1997","unstructured":"Loehrer, P. J. Sr. et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. \n                           15, 3093\u20139 (1997).","journal-title":"J Clin Oncol."},{"key":"12909_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ijrobp.2004.05.013","volume":"60","author":"G Zhu","year":"2004","unstructured":"Zhu, G. et al. Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients. Int J Radiat Oncol Biol Phys. \n                           60, 1113\u20139 (2004).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"12909_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0167-8140(90)90154-O","volume":"19","author":"A Urgesi","year":"1990","unstructured":"Urgesi, A. et al. Role of radiation therapy in locally advanced thymoma. Radiother Oncol. \n                           19, 273\u201380 (1990).","journal-title":"Radiother Oncol."},{"key":"12909_CR25","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1200\/JCO.1994.12.7.1484","volume":"12","author":"IF Ciernik","year":"1994","unstructured":"Ciernik, I. F. et al. Prognostic factors and outcome of incompletely resectedinvasive thymoma following radiation therapy. J Clin Oncol. \n                           12, 1484\u201390 (1994).","journal-title":"J Clin Oncol."},{"key":"12909_CR26","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1002\/cncr.10588","volume":"94","author":"K Ogawa","year":"2002","unstructured":"Ogawa, K. et al. Treatment and prognosisof thymic carcinoma: a retrospectiveanalysis of 40 cases. Cancer. \n                           94, 3115\u20139 (2002).","journal-title":"Cancer."},{"key":"12909_CR27","first-page":"504","volume":"118","author":"J Vogel","year":"2016","unstructured":"Vogel, J. et al. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment. Radio & Oncol. \n                           118, 504\u2013509 (2016).","journal-title":"Oncol."},{"key":"12909_CR28","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/JTO.0000000000000269","volume":"9","author":"J Huang","year":"2014","unstructured":"Huang, J. et al. Development of the international thymic malignancy interest group international database: an unprecedented resource for the study of a rare group of tumors. J Thorac Oncol. \n                           9, 1573\u20138 (2014).","journal-title":"J Thorac Oncol."},{"key":"12909_CR29","doi-asserted-by":"publisher","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","volume":"6","author":"FC Detterbeck","year":"2011","unstructured":"Detterbeck, F. C. et al. The Masaoka-Koga stageclassification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. \n                           6, S1710\u20136 (2011).","journal-title":"J Thorac Oncol."},{"key":"12909_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00432-009-0701-6","volume":"136","author":"ZX Yang","year":"2010","unstructured":"Yang, Z. X. et al. Clinical study of recombinant adenovirus-p53 combined withfractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol. \n                           136, 625\u201330 (2010).","journal-title":"J Cancer Res Clin Oncol."},{"key":"12909_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0369-x","volume":"31","author":"C Li","year":"2014","unstructured":"Li, C. et al. Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study. Med Oncol. \n                           31, 369 (2014).","journal-title":"Med Oncol."},{"key":"12909_CR32","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.ijrobp.2010.12.035","volume":"81","author":"J Wang","year":"2011","unstructured":"Wang, J. et al. Prospective study of epidermal growth factor receptor tyrosinekinase inhibitors concurrent with individualized radiotherapy forpatients with locally advanced or metastatic non-small-cell lungcancer. Int J Radiat Oncol Biol Phys \n                           81, e59\u201365 (2011).","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12909-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T12:12:40Z","timestamp":1671797560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12909-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["12909"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-12909-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,19]]},"assertion":[{"value":"17 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13549"}}